

## DENVER HEALTH AND HOSPITAL AUTHORITY

**BOARD MEETING** 

601 Broadway, 9<sup>th</sup> Floor, Room 927 Thursday, August 22, 2019

1:30 p.m. – 4:30 p.m.

AGENDA		
1:30 – 1:35	I. A. Call to Order and Approval of July 25, 2019 Meeting Minutes (Action) B. Conflict of Interest Disclosure Statement C. Public Comment (none scheduled)	
1:35 – 2:00	<ul> <li>II. Medical Staff/Quality</li> <li>A. Medical Staff Appointments/QSSIC Comments – Dr. Lavonas (5 minutes)(Action)</li> <li>B. Medical Staff Executive Committee (MSEC) Update – Dr. Lavonas (10 minutes)</li> <li>C. Quality, Safety, and Service Improvement Committee (QSSIC) – Fernando Carreira, M.D. (10 minutes)</li> </ul>	
2:00 – 2:05	<ul> <li>III. Consent Calendar (5 minutes) (Action)</li> <li>A. Approval of Resolution Authorizing Bond Issuance</li> <li>B. Approval of Contract with UCD-SOM for Radiology Services</li> </ul>	
	<b>BACKGROUND</b> The Consent Calendar allows the Board to approve multiple routine agenda items using a single motion and vote without the need for discussion. Board members are provided with the materials for each Consent Calendar item prior to the Board meeting. Upon request, any item may be discussed and voted upon separately by the Board.	
	PURPOSE To approve the Consent Calendar using a single motion and vote.	
	ANTICIPATED OUTCOME Approval of the Consent Calendar.	
2:05 - 3:05	IV. Executive Session – Deliberative Process A. Master Plan Update – Jensen and Partners (1 hour) (Informational)	
	<b>BACKGROUND</b> Colorado Revised Statute §24-6-402 (4), (c), (e) and (g) allows the Board to discuss confidential matters in Executive Session and C.R.S. §24-72-204 (3) (a) (IV) and (XIII) allows the Board to review and discuss confidential materials pursuant to the deliberative process privilege.	

	PURPOSE
	To discuss confidential matters subject to the deliberative process privilege.
	ANTICIPATED OUTCOME Board discussion and input regarding the above-referenced matter. Any issue requiring Board approval will be subject to a vote and related discussion in open session.
3:05 – 3:15	-10 Minute Break - (Bio and Cell Phone Break)
3:15 – 3:35	V. New Business A. CEO Report – Robin Wittenstein (20 minutes) (Informational)
	<b>BACKGROUND</b> This is a recurring report and addresses topics as determined by the CEO.
	<b>PURPOSE</b> To provide an update on metric progress and operational goals.
	ANTICIPATED OUTCOME Board discussion and input.
3:35 - 4:00	<ul> <li>VI. Committee and Board Member Reports</li> <li>A. Finance, Audit, and Compliance Committee – Kevin Quinn (5 minutes)</li> <li>B. CHS Report – Susan Powers (5 minutes)</li> <li>C. DHMP Report – Rus Heise (5 minutes)</li> <li>D. Chair's Report – Anne Warhover (10 minutes)</li> </ul>
	<b>BACKGROUND</b> These committee reports are standing agenda items.
	<b>PURPOSE</b> To advise the Board as to the status of each of the committees listed above.
	<b>ANTICIPATED OUTCOME</b> Board discussion and input following each committee report.
4:00 – 4:20	<ul> <li>VII.Executive Session – Deliberative Process and Attorney - Client Privileges</li> <li>A. Opioid Litigation Update – Robin Wittenstein and Scott Hoye (Informational)</li> <li>B. CEO Review Process – Anne Warhover (20 minutes) (Discussion)</li> </ul>
	<b>BACKGROUND</b> Colorado Revised Statute §24-6-402 (4), (c), (e) and (g) allows the Board to discuss confidential matters in Executive Session; C.R.S. §24-72-204 (3) (a) (IV) and (XIII) allows the Board to review and discuss confidential materials pursuant to the deliberative process privilege; and, C.R.S. §24-6-402(4)(b) allows the Board to receive confidential legal advice pursuant to the attorney-client privilege.

## PURPOSE

To discuss confidential matters subject to the deliberative process and attorney-client privileges.

## ANTICIPATED OUTCOME

Board discussion and input regarding the above-referenced matters. Any issue requiring Board approval will be subject to a vote and related discussion in open session.